Literature DB >> 30864177

Determinants of Quality of Life in Patients With Intestinal Failure Receiving Long-Term Parenteral Nutrition Using the SF-36 Questionnaire: A German Single-Center Prospective Observational Study.

Elisabeth Blüthner1,2, Jan Bednarsch3, Martin Stockmann1,4, Mirjam Karber2,5, Sophie Pevny2, Sebastian Maasberg2,6, Undine A Gerlach1, Andreas Pascher1,7, Bertram Wiedenmann2, Johann Pratschke1, Ulrich-Frank Pape2,6.   

Abstract

BACKGROUND: Parenteral nutrition (PN) is a life-sustaining therapy for patients with chronic intestinal failure (IF) but inevitably has an impact on patients' quality of life (QoL). The purpose of this study was to examine multiple aspects of QoL by utilizing the standardized Short Form 36 (SF-36) health survey.
METHODS: Between 2014 and 2017, a total of 90 adult patients with IF who were receiving PN were prospectively enrolled in an observational study. All subjects underwent nutrition status assessment, liver assessment, blood tests, and QoL assessment based on the SF-36. Univariate and multivariable analyses were performed to identify determinants of 8 domains and 2 summary scales of the SF-36.
RESULTS: Analysis of the SF-36 questionnaire data showed that QoL was significantly worse compared with the general German population across all categories. Multivariable analysis revealed that bioelectrical impedance analysis of phase angle (1/10 categories), stoma/fistula (4/10 categories), oral intake (4/10 categories), infusions per week (1/10 categories), duration of PN (1/10 categories), citrulline (4/10 categories), and hemoglobin levels (1/10 categories) are independent risk factors affecting QoL.
CONCLUSION: This study uses the largest cohort of IF patients assessed by the standardized SF-36 questionnaire to comprehensively analyze QoL. Presence of oral intake, presence of ostomy, and citrulline levels were independently correlated with 4 of 10 categories of the SF-36. These results indicate that to improve QoL for IF patients, clinical care should focus on addressing the social and emotional value of oral intake, educational interventions, early stoma closure, and application of new targeted therapies.
© 2019 American Society for Parenteral and Enteral Nutrition.

Entities:  

Keywords:  SF-36; intestinal failure; parenteral nutrition; quality of life

Year:  2019        PMID: 30864177     DOI: 10.1002/jpen.1531

Source DB:  PubMed          Journal:  JPEN J Parenter Enteral Nutr        ISSN: 0148-6071            Impact factor:   4.016


  4 in total

1.  Teduglutide for the treatment of adults with intestinal failure associated with short bowel syndrome: pooled safety data from four clinical trials.

Authors:  Ulrich-Frank Pape; Kishore R Iyer; Palle B Jeppesen; Marek Kunecki; Loris Pironi; Stéphane M Schneider; Douglas L Seidner; Hak-Myung Lee; John Caminis
Journal:  Therap Adv Gastroenterol       Date:  2020-04-20       Impact factor: 4.409

2.  Assessing Non-Invasive Liver Function in Patients with Intestinal Failure Receiving Total Parenteral Nutrition-Results from the Prospective PNLiver Trial.

Authors:  Elisabeth Blüthner; Ulrich-Frank Pape; Martin Stockmann; Mirjam Karber; Sebastian Maasberg; Sophie Pevny; Undine Gerlach-Runge; Andreas Pascher; Johann Pratschke; Frank Tacke; Jan Bednarsch
Journal:  Nutrients       Date:  2020-04-26       Impact factor: 5.717

3.  Impact of intestinal failure and parenteral support on adult patients with short-bowel syndrome: A multinational, noninterventional, cross-sectional survey.

Authors:  Palle B Jeppesen; Saeid Shahraz; Thomas Hopkins; Andrew Worsfold; Elisabeth Genestin
Journal:  JPEN J Parenter Enteral Nutr       Date:  2022-04-13       Impact factor: 3.896

4.  Safety and Efficacy of Teduglutide in Pediatric Patients With Intestinal Failure due to Short Bowel Syndrome: A 24-Week, Phase III Study.

Authors:  Samuel A Kocoshis; Russell J Merritt; Susan Hill; Susan Protheroe; Beth A Carter; Simon Horslen; Simin Hu; Stuart S Kaufman; David F Mercer; Mikko P Pakarinen; Robert S Venick; Paul W Wales; Andrew A Grimm
Journal:  JPEN J Parenter Enteral Nutr       Date:  2019-09-08       Impact factor: 4.016

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.